{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:04:20Z","timestamp":1773342260408,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-025-03988-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:59:37Z","timestamp":1770361177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing patient risk, benefit, and outcomes in drug development: a decade of sorafenib clinical trials"],"prefix":"10.1007","volume":"82","author":[{"given":"Logan","family":"Corwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griffin K.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"McIntire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriana","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstien","family":"Minley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"3988_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1126\/science.1160622","volume":"321","author":"DG Contopoulos-Ioannidis","year":"2008","unstructured":"Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JPA (2008) Life cycle of translational research for medical interventions. Science 321:1298\u20131299","journal-title":"Science"},{"key":"3988_CR2","doi-asserted-by":"publisher","unstructured":"Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Metin G\u00fclmezoglu A, Howells DW, Ioannidis JPA, Oliver S (2014) How to increase value and reduce waste when research priorities are set. [Preprint]. https:\/\/doi.org\/10.1016\/s0140-6736(13)62229-1","DOI":"10.1016\/s0140-6736(13)62229-1"},{"key":"3988_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0140-6736(13)62227-8","volume":"383","author":"JPA Ioannidis","year":"2014","unstructured":"Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R (2014) Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383:166\u2013175","journal-title":"Lancet"},{"key":"3988_CR4","first-page":"651","volume":"3","author":"RC Mohs","year":"2017","unstructured":"Mohs RC, Greig NH (2017) Drug discovery and development: role of basic biological research. Alzheimers Dement 3:651\u2013657","journal-title":"Alzheimers Dement"},{"key":"3988_CR5","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J (2020) Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA 323:844\u2013853","journal-title":"JAMA"},{"key":"3988_CR6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","volume":"177","author":"V Prasad","year":"2017","unstructured":"Prasad V, Mailankody S (2017) Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 177:1569\u20131575","journal-title":"JAMA Intern Med"},{"key":"3988_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2009.295","volume":"87","author":"JA DiMasi","year":"2010","unstructured":"DiMasi JA, Feldman L, Seckler A, Wilson A (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87:272\u2013277","journal-title":"Clin Pharmacol Ther"},{"key":"3988_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40\u201351","journal-title":"Nat Biotechnol"},{"key":"3988_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J, Sarpatwari A (2016) The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 316:858\u2013871","journal-title":"JAMA"},{"key":"3988_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/21507716.2011.653472","volume":"3","author":"CM Ulrich","year":"2012","unstructured":"Ulrich CM, Knafl KA, Ratcliffe SJ, Richmond TS, Grady C, Miller-Davis C, Wallen GR (2012) Developing a model of the benefits and burdens of research participation in cancer clinical trials. AJOB Prim Res 3:10\u201323","journal-title":"AJOB Prim Res"},{"key":"3988_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1634\/theoncologist.2015-0481","volume":"21","author":"RD Nipp","year":"2016","unstructured":"Nipp RD, Lee H, Powell E, Birrer NE, Poles E, Finkelstein D, Winkfield K, Percac-Lima S, Chabner B, Moy B (2016) Financial burden of cancer clinical trial participation and the impact of a cancer care equity program. Oncologist 21:467\u2013474","journal-title":"Oncologist"},{"key":"3988_CR12","unstructured":"World Medical Association, WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Participants (2013). https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/"},{"key":"3988_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-019-0287-0","volume":"17","author":"BG Carlisle","year":"2020","unstructured":"Carlisle BG, Zheng T, Kimmelman J (2020) Imatinib and the long tail of targeted drug development. Nat Rev Clin Oncol 17:1\u20133","journal-title":"Nat Rev Clin Oncol"},{"key":"3988_CR14","doi-asserted-by":"publisher","first-page":"djv292","DOI":"10.1093\/jnci\/djv292","volume":"108","author":"B Carlisle","year":"2016","unstructured":"Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey S, London AJ, Kimmelman J (2016) Benefit, risk, and outcomes in drug development: a systematic review of sunitinib. J Natl Cancer Inst 108:djv292","journal-title":"J Natl Cancer Inst"},{"key":"3988_CR15","doi-asserted-by":"publisher","unstructured":"Carlisle B, Mattina J, Zheng T, Kimmelman J (2019) Patient benefit and risk in anticancer drug development: A systematic review of the ixabepilone trial portfolio. medRxiv. https:\/\/doi.org\/10.1101\/19003467","DOI":"10.1101\/19003467"},{"key":"3988_CR16","doi-asserted-by":"publisher","first-page":"e2000487","DOI":"10.1371\/journal.pbio.2000487","volume":"15","author":"J Mattina","year":"2017","unstructured":"Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J (2017) Inefficiencies and patient burdens in the development of the targeted cancer drug Sorafenib: a systematic review. PLoS Biol 15:e2000487","journal-title":"PLoS Biol"},{"key":"3988_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5195\/jmla.2017.88","volume":"105","author":"ED Foster","year":"2017","unstructured":"Foster ED, Deardorff A (2017) Open science framework (OSF). J Med Libr Assoc 105:203","journal-title":"J Med Libr Assoc"},{"key":"3988_CR18","doi-asserted-by":"publisher","unstructured":"Gardner T, Kari K, Khan A, Dennis B, Kari K, Snider ST, Ladd C, Rashid M, Hightower B, Thayani Z, Young A, Elfar A, Wright C, Tham L, Jhanji V, Duncan J, Smith T, Pena A, Hall RH, Compton W, McIntire R, Tran AV, Hughes G, Vassar M (2023) 06\/23 June projects: drug landscapes. OSF [Preprint]. https:\/\/doi.org\/10.17605\/OSF.IO\/VDR68","DOI":"10.17605\/OSF.IO\/VDR68"},{"key":"3988_CR19","unstructured":"Cancer Therapy Evaluation Program. Protocol Development. Accessed 25 May 2023 https:\/\/ctep.cancer.gov\/protocolDevelopment"},{"key":"3988_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3988_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:210","journal-title":"Syst Rev"},{"key":"3988_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S, Cao G, Li W-Q, Xu L, Chen H, Wu D, Yang R, Wang K, Liu W, Wang H, Bao Q, Liu M, Hao C, Shen L, Xing B, Wang X (2022) Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology 303:455\u2013464","journal-title":"Radiology"},{"key":"3988_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.dld.2013.09.020","volume":"46","author":"S Cascinu","year":"2014","unstructured":"Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Aitini E, Zagonel V, Caprioni F, Villa F, Mosconi S, Faloppi L, Tonini G, Boni C, Conte P, Di Costanzo F, Cinquini M, Italian Group for the Study of Digestive Tract Cancer (GISCAD) (2014) Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase II study. Dig Liver Dis 46:182\u2013186","journal-title":"Dig Liver Dis"},{"key":"3988_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1745-6215-14-159","volume":"14","author":"SP Hey","year":"2013","unstructured":"Hey SP, Heilig CM, Weijer C (2013) Accumulating evidence and research organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials 14:159","journal-title":"Trials"},{"key":"3988_CR25","unstructured":"U. S Food and Drug Administration, Drugs@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021923"},{"key":"3988_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW (2019) Estimation of clinical trial success rates and related parameters. Biostatistics 20:273\u2013286","journal-title":"Biostatistics"},{"key":"3988_CR27","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","volume":"179","author":"EY Chen","year":"2019","unstructured":"Chen EY, Raghunathan V, Prasad V (2019) An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med 179:915\u2013921","journal-title":"JAMA Intern Med"},{"key":"3988_CR28","doi-asserted-by":"publisher","first-page":"175883592092760","DOI":"10.1177\/1758835920927602","volume":"12","author":"G Fan","year":"2020","unstructured":"Fan G, Wei X, Xu X (2020) Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 12:1758835920927602","journal-title":"Ther Adv Med Oncol"},{"key":"3988_CR29","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10637-013-9976-1","volume":"31","author":"LA Mina","year":"2013","unstructured":"Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R (2013) A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group study BRE06-109. Invest New Drugs 31:1307\u20131310","journal-title":"Invest New Drugs"},{"key":"3988_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.clbc.2017.05.006","volume":"17","author":"J Baselga","year":"2017","unstructured":"Baselga J, Zamagni C, G\u00f3mez P, Bermejo B, Nagai SE, Melichar B, Chan A, M\u00e1ngel L, Bergh J, Costa F (2017) Others, RESILIENCE: phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer. Clin Breast Cancer 17:585\u2013594","journal-title":"Clin Breast Cancer"},{"key":"3988_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.clbc.2016.02.003","volume":"16","author":"DA Yardley","year":"2016","unstructured":"Yardley DA, Dickson N, Drosick D, Earwood C, Inhorn R, Murphy P, Hainsworth JD (2016) Sorafenib plus ixabepilone as first-line treatment of metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase I\/II trial. Clin Breast Cancer 16:180\u2013187","journal-title":"Clin Breast Cancer"},{"key":"3988_CR32","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1097\/JTO.0000000000000693","volume":"10","author":"L Paz-Ares","year":"2015","unstructured":"Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC-H, Wakelee HA, Seto T, Wu Y-L, Novello S, Juh\u00e1sz E, Ar\u00e9n O, Sun Y, Schmelter T, Ong TJ, Pe\u00f1a C, Smit EF, Mok TS (2015) Monotherapy admInistration of sorafenib in patientS wIth nOn-small cell lung cancer (MISSION) trial: A phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol 10:1745\u20131753","journal-title":"J Thorac Oncol"},{"key":"3988_CR33","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2015.66.0084","volume":"34","author":"V Papadimitrakopoulou","year":"2016","unstructured":"Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS (2016) The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 34:3638\u20133647","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03988-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03988-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03988-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:54:28Z","timestamp":1773309268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03988-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3988"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03988-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}